> ## Documentation Index
> Fetch the complete documentation index at: https://docs.hi-doctor.ai/llms.txt
> Use this file to discover all available pages before exploring further.

# Retatrutide

> Retatrutide is not approved anywhere: what the triple-agonist mechanism is, what the trials show so far, and the EU-authorised alternative.

Retatrutide is an experimental once-weekly injection for weight management. It copies three hormones the body already makes — two gut hormones that tell the brain you are full and help steady blood sugar, plus a third involved in how the body burns stored energy. Most approved medicines act on one or two of these; retatrutide acts on three, which is why it is described as a "triple agonist".

<Warning>
  Retatrutide is still being studied. No medicines regulator anywhere has approved it, so it is not made for sale, no pharmacy stocks it, and no doctor in the EU — including Hi-Doctor's — can prescribe it. That is the law, not a limitation of any one clinic.
</Warning>

## Regulatory status

Not yet approved, and not from anyone in the EU. Retatrutide has no marketing authorisation, so it cannot legally be prescribed or dispensed outside a clinical trial.

## What the studies reported

Retatrutide is a Phase 3 investigational medicine. Some trials have reported results, while direct-comparison and long-term outcome studies are still running. Published results so far include a Phase 2 readout in the *New England Journal of Medicine* (DOI 10.1056/NEJMoa2301972) and the TRANSCEND-T2D-1 trial in the *Lancet* (DOI 10.1016/S0140-6736(26)00967-000967-0)).

Seven trial registrations are listed on ClinicalTrials.gov: [NCT05931367](https://clinicaltrials.gov/study/NCT05931367), [NCT05929066](https://clinicaltrials.gov/study/NCT05929066), [NCT05929079](https://clinicaltrials.gov/study/NCT05929079), [NCT05882045](https://clinicaltrials.gov/study/NCT05882045), [NCT06354660](https://clinicaltrials.gov/study/NCT06354660), [NCT06662383](https://clinicaltrials.gov/study/NCT06662383) and [NCT06383390](https://clinicaltrials.gov/study/NCT06383390).

<Note>
  Retatrutide's own comparative side-effect data — including effects the source material flags by name, such as dysesthesia, heart-rate changes and treatment discontinuations reported in its trials — is not part of the public evidence captured for this page. Where a figure isn't published, this page does not estimate one.
</Note>

Regulatory sources also flag caution around the unapproved-drug market: the FDA has raised concerns about unapproved GLP-1 products, and Public Citizen published a retatrutide investigation on 16 June 2026.

## The EU-authorised alternative: Mounjaro

Mounjaro (tirzepatide) has been authorised in the EU since 15 September 2022 (EMA EPAR EMEA/H/C/005620). A licensed doctor can assess whether it is appropriate, and a prescription follows only if the doctor approves. It is a once-weekly dual agonist that activates GIP and GLP-1 receptors.

<Warning>
  These are Mounjaro's own trial results, not retatrutide's. In Mounjaro's SURMOUNT-1 trial, the mean change with placebo was −3.1% at 72 weeks. Results for retatrutide may come from a different dose, duration and patient group, so the figures should not be treated as a direct comparison.
</Warning>

## Other weight-management options a doctor may consider

<CardGroup cols={2}>
  <Card title="Semaglutide (Wegovy / Ozempic)" icon="syringe">
    Weekly GLP-1 receptor agonist. A doctor may prescribe it if your BMI and history match the indications. Requires follow-up.
  </Card>

  <Card title="Tirzepatide (Mounjaro)" icon="syringe">
    Dual GLP-1/GIP agonist. Assessed by the doctor based on comorbidities and your BMI.
  </Card>

  <Card title="Liraglutide (Saxenda)" icon="syringe">
    Daily GLP-1 agonist. Indicated in selected patients with elevated BMI after medical evaluation.
  </Card>

  <Card title="Orlistat 120mg" icon="pills">
    Fat-absorption inhibitor. A non-GLP-1 alternative a doctor may consider based on your history.
  </Card>
</CardGroup>

## Common questions

<AccordionGroup>
  <Accordion title="Is retatrutide approved in the EU?">
    No. Retatrutide is a Phase 3 investigational medicine. No medicines regulator anywhere has approved it, so it cannot legally be prescribed or dispensed outside a clinical trial.
  </Accordion>

  <Accordion title="Can a doctor at Hi-Doctor prescribe retatrutide?">
    No. Retatrutide has no marketing authorisation, so no doctor in the EU — including Hi-Doctor's — can prescribe it. That is the law, not a limitation of any one clinic.
  </Accordion>

  <Accordion title="What stage of development has retatrutide reached?">
    Retatrutide is a Phase 3 investigational medicine. Some trials have reported results, while direct-comparison and long-term outcome studies are still running.
  </Accordion>

  <Accordion title="What is the EU-authorised alternative to retatrutide?">
    Mounjaro (tirzepatide) has been authorised in the EU since 15 September 2022. It is a once-weekly dual agonist that activates GIP and GLP-1 receptors. A licensed doctor can assess whether it is appropriate.
  </Accordion>

  <Accordion title="What other weight-management options does Hi-Doctor offer?">
    A doctor may consider semaglutide (Wegovy), tirzepatide (Mounjaro), liraglutide (Saxenda) or orlistat, depending on your BMI, medical history and clinical suitability. See [Mounjaro](/library/medicines/mounjaro) and [Wegovy](/library/medicines/wegovy) for details.
  </Accordion>
</AccordionGroup>

## How Hi-Doctor handles it

A licensed doctor decides case by case; nothing is ever prescribed without evaluation. See [liraglutide](/library/medicines/liraglutide) and [orlistat](/library/medicines/orlistat) for two EU-authorised options, and [pricing](/essentials/pricing) for how ongoing weight-loss care is billed — medication is always paid separately at the pharmacy.

## Start a consultation

<Card title="Weight-loss consultation" icon="stethoscope" href="https://hi-doctor.ai/consultation/weight-loss/1">
  Answer the weight-loss questionnaire and a registered doctor reviews it.
  They decide whether treatment is appropriate, which one, and at what dose —
  and declining is a normal outcome. See [what it costs](/essentials/pricing)
  and [how the review works](/essentials/how-it-works).
</Card>

<Warning>
  This page is reference information, not medical advice and not a prescription.
  Whether a medicine is appropriate for you is decided by a registered doctor
  after reviewing your consultation.
</Warning>